Trial · NCT00365352
Results by group122
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 122
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) | Placebo | -9.8 | Standard Deviation 7.69 | scores on a scale | |
| Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) | GEn (XP13512/GSK1838262) 1200 mg | -13.0 | Standard Deviation 9.12 | scores on a scale | |
| Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | Placebo | 43 | participants | ||
| Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | GEn (XP13512/GSK1838262) 1200 mg | 86 | participants | ||
| Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF | Placebo | -9.8 | Standard Deviation 7.69 | scores on a scale | |
| Change From Baseline to the End of Treatment (Week 12) in the IRLS Rating Scale Total Score Using LOCF | GEn (XP13512/GSK1838262) 600 mg | -13.8 | Standard Deviation 8.09 | scores on a scale | |
| Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | Placebo | 43 | participants | ||
| Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | GEn (XP13512/GSK1838262) 600 mg | 83 | participants | ||
| Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | Placebo | 13 | participants | ||
| Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | GEn (XP13512/GSK1838262) 600 mg | 36 | participants | ||
| Number of Participants Who Had an Onset of Response to Treatment at the End of Week 1 Based Upon the IRLS Rating Scale Total Score and the Investigator-rated CGI-I Using LOCF | GEn (XP13512/GSK1838262) 1200 mg | 40 | participants | ||
| The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | Placebo | NA | 95% Confidence Interval NA to NA | weeks | |
| The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | GEn (XP13512/GSK1838262) 600 Milligrams(mg) Taken Orally | 4.1 | 95% Confidence Interval 2.1 to 8.1 | weeks | |
| The Time to Onset of the First Response to Treatment on the IRLS Rating Scale Total Score and the Investigator-rated CGI-I | GEn (XP13512/GSK1838262) 1200 mg Taken Orally Once a Day | 2.1 | 95% Confidence Interval 2.1 to 4.0 | weeks | |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Placebo | No RLS Treatment History | -8.8 | Standard Deviation 7.08 | scores on a scale |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | GEn (XP13512/GSK1838262) 600 mg | No RLS Treatment History | -13.7 | Standard Deviation 8.23 | scores on a scale |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | GEn (XP13512/GSK1838262) 1200 mg | No RLS Treatment History | -12.5 | Standard Deviation 8.78 | scores on a scale |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | Placebo | Treatment terminated | -13.3 | Standard Deviation 9.09 | scores on a scale |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | GEn (XP13512/GSK1838262) 600 mg | Treatment terminated | -12.4 | Standard Deviation 7.26 | scores on a scale |
| Mean Change in the IRLS Rating Scale Total Score From Baseline at Week 12 by RLS Treatment History Using LOCF | GEn (XP13512/GSK1838262) 1200 mg | Treatment terminated | -17.1 | Standard Deviation 7.94 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00365352/results